JP5423002B2 - Collagen synthesis promoter containing zinc as an active ingredient - Google Patents
Collagen synthesis promoter containing zinc as an active ingredient Download PDFInfo
- Publication number
- JP5423002B2 JP5423002B2 JP2008522615A JP2008522615A JP5423002B2 JP 5423002 B2 JP5423002 B2 JP 5423002B2 JP 2008522615 A JP2008522615 A JP 2008522615A JP 2008522615 A JP2008522615 A JP 2008522615A JP 5423002 B2 JP5423002 B2 JP 5423002B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen synthesis
- zinc salt
- zinc
- composition
- ubiquinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010035532 Collagen Proteins 0.000 title claims description 92
- 102000008186 Collagen Human genes 0.000 title claims description 92
- 229920001436 collagen Polymers 0.000 title claims description 91
- 230000015572 biosynthetic process Effects 0.000 title claims description 83
- 238000003786 synthesis reaction Methods 0.000 title claims description 82
- 239000004480 active ingredient Substances 0.000 title claims description 12
- 239000011701 zinc Substances 0.000 title description 31
- 229910052725 zinc Inorganic materials 0.000 title description 25
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title description 24
- 230000001737 promoting effect Effects 0.000 claims description 50
- CHCZPSBPZFXDQJ-UHFFFAOYSA-L zinc;2-oxopyrrolidine-1-carboxylate Chemical compound [Zn+2].[O-]C(=O)N1CCCC1=O.[O-]C(=O)N1CCCC1=O CHCZPSBPZFXDQJ-UHFFFAOYSA-L 0.000 claims description 48
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 44
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 43
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 43
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 40
- 229940035936 ubiquinone Drugs 0.000 claims description 40
- -1 amino acid ester Chemical class 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 210000002950 fibroblast Anatomy 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 5
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 description 41
- 210000003491 skin Anatomy 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 23
- 230000000694 effects Effects 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 16
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000037303 wrinkles Effects 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 13
- 230000002500 effect on skin Effects 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 108091006695 Ascorbic-acid transporters Proteins 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000013329 compounding Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011787 zinc oxide Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 5
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- REGPDRSDSZELCD-UHFFFAOYSA-N phenol;zinc Chemical compound [Zn].OC1=CC=CC=C1 REGPDRSDSZELCD-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- 239000011576 zinc lactate Substances 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical class [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940071085 lauroyl glutamate Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940050168 zinc lactate Drugs 0.000 description 4
- 235000000193 zinc lactate Nutrition 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 230000008417 skin turnover Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GLJADRYELJNXDG-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid;zinc Chemical compound [Zn].OC(=O)N1CCCC1=O GLJADRYELJNXDG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010043275 Teratogenicity Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- ZTTORBNKJFMGIM-UWVGGRQHSA-N methyl (2r)-2-acetamido-3-[[(2r)-2-acetamido-3-methoxy-3-oxopropyl]disulfanyl]propanoate Chemical compound COC(=O)[C@@H](NC(C)=O)CSSC[C@H](NC(C)=O)C(=O)OC ZTTORBNKJFMGIM-UWVGGRQHSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000211 teratogenicity Toxicity 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ZSKINHGFQOKUDM-IYEMJOQQSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid;zinc Chemical class [Zn].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZSKINHGFQOKUDM-IYEMJOQQSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- IDHBXJLCYUJUMC-UWVGGRQHSA-N methyl (2r)-2-amino-3-[[(2r)-2-(diacetylamino)-3-methoxy-3-oxopropyl]disulfanyl]propanoate Chemical compound COC(=O)[C@@H](N)CSSC[C@H](N(C(C)=O)C(C)=O)C(=O)OC IDHBXJLCYUJUMC-UWVGGRQHSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- GJBHGUUFMNITCI-QTNFYWBSSA-M sodium;(2s)-2-aminopentanedioate;hydron;hydrate Chemical compound O.[Na+].OC(=O)[C@@H](N)CCC([O-])=O GJBHGUUFMNITCI-QTNFYWBSSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 229940062776 zinc aspartate Drugs 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
- KPKLKIOSPIATFO-QXGOIDDHSA-L zinc;(2s)-2-amino-3-phenylpropanoate Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC1=CC=CC=C1.[O-]C(=O)[C@@H](N)CC1=CC=CC=C1 KPKLKIOSPIATFO-QXGOIDDHSA-L 0.000 description 1
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 1
- WAMAIUZWKRNZBB-WFGSYIHQSA-L zinc;(2s,3s)-2-amino-3-methylpentanoate Chemical compound [Zn+2].CC[C@H](C)[C@H](N)C([O-])=O.CC[C@H](C)[C@H](N)C([O-])=O WAMAIUZWKRNZBB-WFGSYIHQSA-L 0.000 description 1
- GAMIYQSIKAOVTG-UHFFFAOYSA-L zinc;2-aminopentanedioate Chemical compound [Zn+2].[O-]C(=O)C(N)CCC([O-])=O GAMIYQSIKAOVTG-UHFFFAOYSA-L 0.000 description 1
- BUJKOUKORSHUMB-UHFFFAOYSA-L zinc;2-oxopyrrolidine-1-carboxylate;dihydrate Chemical compound O.O.[Zn+2].[O-]C(=O)N1CCCC1=O.[O-]C(=O)N1CCCC1=O BUJKOUKORSHUMB-UHFFFAOYSA-L 0.000 description 1
Images
Description
【技術分野】
【０００１】
本発明はしわを防止するのに有用な、亜鉛を有効成分として含有するコラーゲン合成促進剤、およびこれを含有する組成物に関する。
【背景技術】
【０００２】
皮膚のしわを予防あるいは改善する物質は多く見出されているが、完全に予防や改善が実感できる安全な物質はなく、未だ多くの研究がなされている。しわの形成が起きる原因は種々報告されているが、その一つに肌の乾燥があげられる。皮膚角層中の水分量が減少することで、皮膚の小じわは現れることは良く知られた事実である。このことから、皮膚角層中の水分量を高く維持するため保湿成分が利用されている。我々自身の皮膚角層が持っている保湿成分としてＮＭＦ（Ｎａｔｕｒａｌ Ｍｏｉｓｔｕｒｉｚｉｎｇ Ｆａｃｔｏｒ）が有名であるが、その構成要素であるアミノ酸自身にも角層中の水分を高く保持するものも見出されている。また、プラセンタエキスやビタミン類などの細胞賦活成分により皮膚角化細胞のターンオーバーを促進し、しわの予防・改善を行おうとする提案もなされている。
【０００３】
乾燥とは異なる原因として、皮膚の老化に伴うしわやたるみの大きな原因として、真皮中のコラーゲン量の減少が関係していると考えられる。皮膚中のコラーゲンは真皮の細胞外マトリックスの成分であり結合組織として重要な役割を果たしている。コラーゲン量は皮膚の柔らかさや張りを構成する重要な要因である。
【０００４】
皮膚組織におけるコラーゲン量を増加させるためには、ＵＶ照射により誘導されるコラーゲナーゼ活性を阻害し、コラーゲンの分解を抑制すること、および、コラーゲン合成を促進することが重要である。コラーゲン合成はビタミンやホルモン、サイトカインなどが作用することで促進することが知られている。
【０００５】
コラーゲン合成を促す製品としてコラーゲンタンパクやコラーゲン組成アミノ酸組成物などが市販されているが、そのコラーゲン合成促進効果は明確でない。
【０００６】
また、レチノイド、レチノール、レチノイン酸がコラーゲンの合成を促進させることが知られているが、催奇性、副作用も報告されており、より安全で、効果の高いコラーゲン合成促進剤が求められている。
【０００７】
ユビキノンは１９５７年にウシの心臓の細胞内ミトコンドリアから単離・発見された化合物で、コエンザイムＱ１０、補酵素Ｑ１０、あるいは単にＣｏＱ１０とも呼ばれる。ユビキノンは体内で作り出され、多くの臓器に存在する。その働きの１つに細胞内ミトコンドリアでのエネルギーの産生がある。ミトコンドリア内において、糖や脂質などを利用し電子伝達系、ＴＣＡサイクルを介して、ＡＴＰという高エネルギー分子を産生する。すなわち、ユビキノンは電子伝達系で働き、ＡＴＰ産生に寄与する。心臓でのユビキノンは４０歳を過ぎると２０歳時の約半分までその生成量が減少すると言われている。皮膚においては、いまだユビキノンに関する詳しいデータは少ないが、他の臓器と同様に加齢と共にユビキノン濃度は減少すると考えられる。
【０００８】
また、ユビキノンのもう１つの働きは抗酸化効果である。皮膚は紫外線などに暴露される機会が多いため、皮膚内での酸化反応が常に引き起こされている。この酸化反応を防ぐため、多くのユビキノンが生成され利用されていると考えられる。２００４年には、化粧品としてユビキノンが利用可能となり、多くの化粧品に使われるようになってきたが、エネルギー産生促進による肌のターンオーバーの促進や、抗酸化効果以外では、ユビキノンの皮膚に対する具体的な効果については未だ不明な点も多い。
【０００９】
一方、亜鉛については、無機亜鉛塩の一種である酸化亜鉛が、おむつかぶれを抑制すると報告されている（例えば、ＦＥＢＳ Ｌｅｔｔｅｒｓ，３８４巻，９２〜９６ページ、１９９６年）。しかしながら、この化合物は水にも油性成分にも難溶で、化粧品や皮膚外用剤の成分として用いることが難しい。
【００１０】
有機亜鉛塩の一種であるグリシン亜鉛塩について、メタロチオネインの誘導促進作用を有することが知られている（特開２００５−２４７７２９号公報）。これは抗酸化効果やラジカル補足能などの経路により、メラニン合成阻害や細胞毒性阻害などのＵＶによる皮膚損傷の抑制作用である。しかしながらグリシン亜鉛塩のコラーゲン合成に対する影響は知られていない。
【００１１】
同じく有機亜鉛塩の一種であるピロリドンカルボン酸亜鉛塩やアシルアミノ酸亜鉛塩について、ＵＶにより惹起されるＡＰ−１やＮＦ−κＢなどの炎症因子を抑制することが知られている（特開２００６−０２２０９０号公報、国際公開ＷＯ２００５／１２３０６２号パンフレット）。しかしながらピロリドンカルボン酸亜鉛塩やアシルアミノ酸亜鉛塩のコラーゲン合成に関する作用は知られていない。
【００１２】
その他、有機亜鉛塩や無機亜鉛塩について、収れん作用、消炎作用、白色顔料、紫外線防御剤、消臭・殺菌剤の用途で化粧料組成物に配合することが知られているが、効果を期待できる濃度領域近傍での利用は皮膚に対する刺激性から、化粧品としての利用が難しかった。また低濃度での利用では、皮膚への上記有効性を見出せず、亜鉛塩の化粧料への配合は進んでいないのが現状である。
【発明の開示】
【００１３】
本発明者らは、保湿や、肌のターンオーバーの促進によるしわの改善ではなく、コラーゲン合成によるしわの改善を目的として鋭意検討を重ねた結果、亜鉛をヒト真皮繊維芽細胞に導入することにより、アスコルビン酸トランスポーターの発現促進効果を有することを見出し、これに伴いコラーゲン合成促進効果が得られることを見出した。
【００１４】
アスコルビン酸トランスポーターは、細胞へのアスコルビン酸の取り込みを促進する膜タンパク質であり（Ｈｉｒｏｙａｓｕ Ｔｓｕｋａｇｕｃｈｉ ｅｔｃ （１９９９）Ｎａｔｕｒｅ ３９９，７０−７５を参照せよ）、アスコルビン酸トランスポーターの発現増強により、真皮繊維芽細胞においてコラーゲン合成に必須なアスコルビン酸の細胞内への取り込みが増加し、コラーゲン合成が促進される。
【００１５】
さらに、驚くべきことに、従来コラーゲン合成促進効果が知られていなかったユビキノンに、亜鉛塩の一つであるピロリドンカルボン酸亜鉛塩を添加することにより、極めて顕著にコラーゲン合成が相乗的に促進されることを見出した。
【００１６】
本発明の目的は、上記の知見に基づき、優れたコラーゲン合成作用を有するコラーゲン合成促進剤、およびこれを含有する化粧料組成物を得ることにある。
【課題を解決するための手段】
【００１７】
すなわち、本発明は、亜鉛を有効成分として含有することを特徴とするコラーゲン合成促進用組成物、およびユビキノンとピロリドンカルボン酸亜鉛塩を有効成分として含有することを特徴とするコラーゲン合成促進用組成物に関する。
【００１８】
皮膚刺激性、細胞内への導入効率などの観点から、現実的に実施可能な亜鉛の導入方法としては、亜鉛を亜鉛塩にして、一定濃度、皮膚に塗布することが必要であり、具体的には以下の発明を含む。
【００１９】
（１）亜鉛を有効成分として含有するコラーゲン合成促進剤。
（２）亜鉛が、ピロリドンカルボン酸亜鉛塩、グルコン酸亜鉛塩、フェノールスルホン酸亜鉛、乳酸亜鉛塩、各種アミノ酸亜鉛塩、アシルアミノ酸亜鉛塩、硫酸亜鉛、塩化亜鉛および酸化亜鉛からなる群より選択される化合物である、（１）記載のコラーゲン合成促進剤。
（３）亜鉛が、ピロリドンカルボン酸亜鉛塩である（１）記載のコラーゲン合成促進剤。
（４）ピロリドンカルボン酸亜鉛塩とユビキノンを有効成分として含有するコラーゲン合成促進剤。
（５）コラーゲン合成が、ヒト繊維芽細胞のアスコルビン酸トランスポーターの発現増強を介してされるものである、上記（１）から（４）に記載のコラーゲン合成促進剤。
（６）亜鉛を、有効成分として配合することを特徴とする、コラーゲン合成促進用組成物。
（７）亜鉛が、ピロリドンカルボン酸亜鉛塩、グルコン酸亜鉛塩、フェノールスルホン酸亜鉛、乳酸亜鉛塩、各種アミノ酸亜鉛塩、アシルアミノ酸亜鉛塩、硫酸亜鉛、塩化亜鉛および酸化亜鉛からなる群より選択される化合物である、（６）記載のコラーゲン合成促進用組成物。
（８）亜鉛が、ピロリドンカルボン酸亜鉛塩である（６）記載のコラーゲン合成促進用組成物。
（９）ピロリドンカルボン酸亜鉛塩とユビキノンを有効成分として配合することを特徴とする、コラーゲン合成促進用組成物。
（１０）亜鉛を、組成物中に１μＭ〜１００ｍＭの濃度で存在するように配合することを特徴とする、上記（６）〜（９）に記載のコラーゲン合成促進用組成物。
（１１）さらに、Ｎ−アシル酸性アミノ酸エステル、またはアミノ酸誘導体が配合される、上記（６）〜（１０）に記載のコラーゲン合成促進用組成物。
（１２）軟膏、化粧水、ローション、クリーム、乳液、美容液、パック、ファンデーション、液体ハンドソープ、シャンプー、または毛髪用化粧水である上記（６）〜（１１）に記載のコラーゲン合成促進用組成物。
（１３）亜鉛を、有効成分として配合することを特徴とする、しわの予防剤または治療剤。
（１４）亜鉛が、ピロリドンカルボン酸亜鉛塩、グルコン酸亜鉛塩、フェノールスルホン酸亜鉛、乳酸亜鉛塩、各種アミノ酸亜鉛塩、アシルアミノ酸亜鉛塩、硫酸亜鉛、塩化亜鉛および酸化亜鉛からなる群より選択される化合物である、（１３）記載のしわの予防剤または治療剤。
（１５）亜鉛が、ピロリドンカルボン酸亜鉛塩である（１３）記載のしわの予防剤または治療剤。
（１６）ピロリドンカルボン酸亜鉛塩とユビキノンを有効成分として配合することを特徴とする、しわの予防剤または治療剤。
（１７）コラーゲン合成促進のための亜鉛の使用。
（１８）コラーゲン合成促進のための、ピロリドンカルボン酸亜鉛塩、グルコン酸亜鉛塩、フェノールスルホン酸亜鉛、乳酸亜鉛塩、各種アミノ酸亜鉛塩、アシルアミノ酸亜鉛塩、硫酸亜鉛、塩化亜鉛および酸化亜鉛からなる群より選択される亜鉛塩の使用。
（１９）コラーゲン合成促進のためのピロリドンカルボン酸亜鉛塩の使用。
（２０）コラーゲン合成促進のためのピロリドンカルボン酸亜鉛塩とユビキノンの併用。
（２１）上記（６）〜（１２）に記載の組成物を皮膚に塗布することを特徴とするコラーゲン合成を促進する方法。
（２２）ユビキノンとピロリドンカルボン酸亜鉛塩が、５０：１〜０．１：１の重量比率で含有される、上記（４）に記載のコラーゲン合成促進剤。
（２３）０．０００１重量％〜１０重量％のユビキノンおよび０．００００３５重量％〜３．５重量％のピロリドンカルボン酸亜鉛塩を含有することを特徴とするコラーゲン合成促進用組成物。
（２４）０．０００１重量％〜１０重量％のユビキノンおよび０．００００３５重量％〜３．５重量％のピロリドンカルボン酸亜鉛塩を含有することを特徴とするしわの予防剤または治療剤。
（２５）０．０００１重量％〜１０重量％のユビキノンおよび０．００００３５重量％〜３．５重量％のピロリドンカルボン酸亜鉛塩を含有する組成物を皮膚に塗布することを特徴とするコラーゲン合成を促進する方法。
【図面の簡単な説明】
【００２０】
図１は、ヒト真皮繊維芽細胞を用いた亜鉛塩のコラーゲン合成促進効果を確認した図である。
図２は、ヒト真皮繊維芽細胞を用いたピロリドンカルボン酸亜鉛塩によるコラーゲン合成促進効果を確認した図である。
図３は、ピロリドンカルボン酸亜鉛塩によるアスコルビン酸トランスポーターｍＲＮＡ発現増強効果を確認した図である。
図４は、ヒト真皮繊維芽細胞を用いたピロリドンカルボン酸亜鉛塩およびユビキノンによるコラーゲン合成促進効果を確認した図である。
図５は、ピロリドンカルボン酸亜鉛塩配合処方による三次元培養ヒト皮膚におけるコラーゲン合成促進効果を確認した図である。
【発明の詳細な説明】
【発明を実施するための最良の形態】
【００２１】
以下、本発明の詳細を説明する。
【００２２】
本発明に用いられる亜鉛は、皮膚刺激性、細胞への導入効率などの観点から、現実的に亜鉛を亜鉛塩にして、一定濃度、皮膚に塗布することが必要である。この場合有機亜鉛塩および無機亜鉛塩のいずれも使用することができる。有機亜鉛塩としては、ピロリドンカルボン酸亜鉛塩、グルコン酸亜鉛塩、フェノールスルホン酸亜鉛、乳酸亜鉛塩、各種アミノ酸亜鉛塩、アシルアミノ酸亜鉛塩、などが含まれる。無機亜鉛塩としては、硫酸亜鉛、塩化亜鉛、酸化亜鉛などが含まれる。
【００２３】
アミノ酸亜鉛塩としては、グリシン亜鉛塩、アラニン亜鉛塩、バリン亜鉛塩、ロイシン亜鉛塩、イソロイシン亜鉛塩、フェニルアラニン亜鉛塩、メチオニン亜鉛塩、トリプトファン亜鉛塩、アスパラギン亜鉛塩、グルタミン亜鉛塩、セリン亜鉛塩、スレオニン亜鉛塩、システイン亜鉛塩、チロシン亜鉛塩、アスパラギン酸亜鉛塩、グルタミン酸亜鉛塩、リジン亜鉛塩、アルギニン亜鉛塩、若しくはヒスチジン亜鉛塩などの各種アミノ酸亜鉛塩が挙げられる。
【００２４】
アシルアミノ酸亜鉛塩とは、アミノ酸のアミノ基にアシル基が結合した化合物の亜鉛塩であるが、例えば、アシルアミノ酸としては以下の構造式を有する化合物が挙げられる。
【００２５】
【化１】
【００２６】
（上記（Ｉ）中、Ｒ１は炭素原子数２〜２２のアシル基、Ｒ２は水素原子または、炭素数１〜６の直鎖または分岐鎖アルキル基を、Ｒ３はアミノ酸であるバリン、ロイシン、イソロイシン、フェニルアラニン、メチオニン、トリプトファン、アスパラギン、グルタミン、セリン、スレオニン、システイン、チロシン、アスパラギン酸、グルタミン酸、リジン、アルギニン、ヒスチジン、アラニンの側鎖または、水素原子を表し、ｎは０または１の整数を表す。）
【００２７】
コラーゲン合成促進効果を高めるという観点において、血流促進効果を持つピロリドンカルボン酸の亜鉛塩は、血管内のアスコルビン酸などの有用物質を塗布部位に集めることが期待されるため、アスコルビン酸トランスポーターの発現促進効果がより顕著にコラーゲン合成促進効果に反映される亜鉛塩である。
【００２８】
ピロリドンカルボン酸亜鉛塩（以下、ＰＣＡ亜鉛塩、ＰＣＡＺｎ塩ともいう）とは、２−ピロリドン−５−カルボン酸の亜鉛塩であって、各種水和物であってもよい。実施例において使用したピロリドンカルボン酸亜鉛塩は２水和物であり、以下の構造を有する。
【００２９】
【化２】
【００３０】
ピロリドンカルボン酸亜鉛塩は、Ｄ体、Ｌ体もしくはＤＬ体（Ｄ体とＬ体の混合物）のいずれを用いてもよい。例えば、Ｌ−ＰＣＡ亜鉛塩やＤＬ−ＰＣＡ亜鉛塩を用いることができる。これらを単独あるいは混合して用いることが可能であり、ＤＬ体を用いる場合、Ｄ体とＬ体の比率は特に限定されない。
【００３１】
本発明のコラーゲン合成促進剤は、化粧料や皮膚外用剤などの組成物に配合して使用される。この際、その配合量を１μＭ〜１００ｍＭ（ＰＣＡ亜鉛塩として０．００００３５重量％〜３．５重量％）、好ましくは、１μＭ〜１０ｍＭ（ＰＣＡ亜鉛塩として０．００００３５重量％〜０．３５重量％）、更に好ましくは、１μＭ〜１ｍＭ（ＰＣＡ亜鉛塩として０．００００３５重量％〜０．０３５重量％）程度のごく少量配合することが重要である。３．５重量％以上の配合では皮膚に対して刺激感が生じる、あるいは、きしみ感などが発生する問題があり、また、培養皮膚細胞を用いた検討によれば、高濃度ではコラーゲン合成促進効果は起こらなくなり、好ましくない。
【００３２】
本発明のコラーゲン合成促進剤を化粧料や皮膚外用剤などの組成物に配合するとき、これらの成分以外に、一般に化粧料あるいは皮膚外用剤として使用される成分を本発明の効果を阻害しない範囲で添加することができる。
【００３３】
本発明の第二の態様として、ユビキノンとピロリドンカルボン酸亜鉛塩を有効成分として含有するコラーゲン合成促進剤に関する。今まで説明したように、ピロリドンカルボン酸亜鉛塩を単独でコラーゲン合成促進剤として使用することができるが、ユビキノンと併用して用いると、驚くべき相乗効果を有するコラーゲン合成促進剤として使用することができる。これにより、肌のターンオーバーの促進や、抗酸化効果による、しわの改善ではなく、コラーゲン合成によるしわの改善が期待できる。
【００３４】
本発明においてユビキノンとは、２，３−ジメトキシ−５−メチル−６−ポリプレニル−１，４−ベンゾキノンの側鎖のイソプレン単位が１０のユビキノン類であり、本発明の効果を適切に発現させるためには、ユビキノンの配合量は０．０００１重量％以上にすることが好ましく、０．０１重量％以上にすることがより好ましく、０．０３重量％以上にすることがさらに好ましい。また、ユビキノンの配合量を必要以上に多くすると、結晶化したり、製品の色が黄変するおそれがあるので、１０重量％以下にすることが好ましく、１重量％以下にすることがより好ましく、０．１重量％以下にすることがさらに好ましい。ピロリドンカルボン酸亜鉛塩は、その効果を適切に発現させるためには、ユビキノンとピロリドンカルボン酸亜鉛塩の配合比率が、５０：１〜０．１：１の比率で含有されることが好ましい。
【００３５】
また、本発明の更なる態様として、本発明のコラーゲン合成促進剤と、Ｎ−アシル酸性アミノ酸エステル、アミノ酸およびアミノ酸誘導体からなる群より選択される１種また２種以上が同時に配合されてなる組成物に関する。
【００３６】
本発明の組成物に配合することができるＮ−アシル酸性アミノ酸エステルは、次の構造で表されるものであって、
【００３７】
【化３】
【００３８】
（式中のＸおよびＹは双方が同じでも異なっていてもよいが、ＸおよびＹはステロールのエステル生成残基、炭素数８〜３０の直鎖もしくは分岐の液状高級アルキルアルコールもしくはアルケニルアルコール、または炭素数１２〜３８の固形状直鎖もしくは分岐の高級アルコールのエステル生成残基から選ばれる少なくとも１種である。そして、窒素原子に結合するＣＯＲは炭素数８〜２２の直鎖アシル基である。ｎは１または２である。ａ、ｂは０〜１０であり、ｂは０〜１０である。）
【００３９】
特にＮ−アシル酸性ジエステルが好ましく、その好適な具体例としては、例えば、Ｎ−ラウロイルグルタミン酸ジ（コレステリルベヘニルオクチルドデシル）、Ｎ−ラウロイルグルタミン酸ジ（コレステリルオクチルドデシル）、Ｎ−ラウロイルグルタミン酸ジ（フィトステリル２−オクチルドデシル）、Ｎ−ラウロイルグルタミン酸ジ（オクチルドデシルフィトステリルベヘニル）などが挙げられ、それらは、味の素株式会社から、それぞれ、「エルデュウＣＬ−３０１」、「エルデュウＣＬ−２０２」、「エルデュウＰＳ−２０３」、「エルデュウＰＳ−３０４」の商品名で市販されている。
【００４０】
そして、本発明において、このＮ−アシル酸性アミノ酸エステルは、保湿力や整肌性の向上に寄与し、また、安定性の向上にも寄与するが、その効果を適切に発現させるためには、その配合量は、０．０１重量％以上にすることが好ましく、０．１重量％以上にすることがより好ましく、０．５重量％以上にすることがさらに好ましく、また、Ｎ−アシル酸性アミノ酸エステルの配合量を必要以上に多くすると、べたつくおそれがあるので、２０重量％以下にすることが好ましく、１０重量％以下にすることがより好ましく、５重量％以下にすることがさらに好ましい。
【００４１】
アミノ酸またはアミノ酸誘導体は、保湿効果の向上に寄与させるために組成物中に配合されるが、そのアミノ酸としては、例えば、アラニン、アルギニン、アスパラギン、アスパラギン酸、シトルリン、システイン、シスチン、グルタミン、グルタミン酸、グリシン、ヒスチジン、オキシプロリン、イソロイシン、ロイシン、リジン、メチオニン、オルニチン、フェニルアラニン、プロリン、セリン、スレオニン、トリプトファン、チロシン、バリンなどが挙げられ、それらのＬ体、Ｄ体またはＤＬ体のいずれであってもよいし、また、それらの塩であってもよい。そのような塩としては、例えば、ナトリウム塩、カリウム塩、トリエタノールアミン塩などが挙げられる。
【００４２】
また、アミノ酸誘導体としては、前述のアミノ酸を環化、アシル化またはエステル化したものであって、例えば、アセチルグルタミン酸、アセチルメチオニン、アセチルシステイン、Ｎ，Ｎ−ジアセチル−Ｌ−シスチンジメチルエステル、アシルグルタミン酸塩、アシルグリシン塩、アシルアラニン塩、アシルアルギニンエチルエステル塩などが挙げられる。ただし、Ｎ−アシル酸性アミノ酸エステルは含まない。
【００４３】
一般に化粧料あるいは皮膚外用剤に使用されている成分としては、抗酸化剤、抗炎症剤、紫外線吸収剤、美白剤、細胞賦活剤、保湿剤、金属キレート剤、油性原料、界面活性剤、溶剤、高分子物質、粉体物質、色素類、香料、経皮吸収促進剤及びステロイドホルモン等を挙げることができる。
【００４４】
上記亜鉛塩を含有する組成物の形態には特に制限はなく、溶液状、ペースト状、ゲル状、固体状、粉末状等任意の形態をとることができる。また、本発明の組成物は、オイル、ローション、クリーム、乳液、ゲル、シャンプー、ヘアリンス、ヘアコンディショナー、エナメル、ファンデーション、リップスティック、おしろい、パック、軟膏、錠剤、注射液、顆粒、カプセル、香水、パウダー、オーデコロン、歯磨、石鹸、エアゾル、クレンジングフォーム等の他、皮膚老化防止改善剤、皮膚炎症防止改善剤、浴用剤、養毛剤、皮膚美容液、日焼け防止剤、色素性乾皮症・日光蕁麻疹等の光線過敏症の防止改善剤、光アレルギーの防止改善剤、光免疫抑制の防止改善剤あるいは、外傷・あかぎれ・ひびわれ等による肌荒れの防止改善剤、消毒剤、抗菌剤、殺虫剤、害虫駆除剤、角質溶解剤、表皮剥離剤、ニキビの防止改善剤、角化症・乾皮症・魚鱗癬・乾癬等の各種皮膚疾患の防止改善剤等に用いることができる。
【００４５】
更にその他の常用成分を、組成物に本発明の効果を阻害しない範囲で添加することができる。本発明の組成物におけるその他の常用成分としては、防腐剤、褪色防止剤、緩衝剤、にきび用薬剤、ふけ・かゆみ防止剤、制汗防臭剤、熱傷用薬剤、抗ダニ・シラミ剤、角質軟化剤、乾皮症用薬剤、抗ウイルス剤、ホルモン類、ビタミン類、アミノ酸・ペプチド類、タンパク質類、収れん剤、清涼・刺激剤、動植物由来成分、抗生物質、抗真菌剤、育毛剤等を挙げることができる。
【実施例】
【００４６】
以下、本発明を実施例（合成例、試験例および配合例）により更に具体的に説明するが、本発明はこれら実施例に限定されるものではない。尚、これらの実施例において、配合量は重量％で表した。
【００４７】
試験例１．亜鉛塩のコラーゲン合成促進効果
亜鉛塩のコラーゲン合成促進効果を確認するため、２種類の亜鉛塩と、同じくナトリウム塩を調製し、正常ヒト真皮繊維芽細胞からのコラーゲン合成促進効果を評価した。コンフルエント状態になった正常ヒト真皮繊維芽細胞を剥がし、Ｄ−ＭＥＭ（１０％ＦＢＳ含有）中、９６ウェルプレートに播種し、２４時間、飽和水蒸気下、３７℃、５％ＣＯ２にて無菌的に培養した。２４時間後、培地を取り除き、各サンプルを所定の濃度（５０μＭ。２５０μＭアスコルビン酸Ｎａ塩及び２％ＦＢＳ含有）に調製したＤ−ＭＥＭを添加した。４８時間、飽和水蒸気下、３７℃、５％ＣＯ２にて無菌的に培養した。４８時間後、その培養上澄みを採取し、その液中のヒト真皮繊維芽細胞から放出されたＩ型プロコラーゲン量をＥＬＩＳＡにて定量評価した。
結果を図１に示す。グラフから分かるように、２種類の亜鉛塩はともに、コントロールに比べ４８時間での培地中へのコラーゲン合成量が増加した。しかし、対応するナトリウム塩では、培地中のコラーゲン合成量の増加は認められなかった。
【００４８】
試験例２．ＰＣＡＺｎ塩の血流促進効果
ＰＣＡＺｎ塩とその他のＺｎ塩との違いを血流促進効果（血液量増加）から確認した。各サンプルのＺｎ塩及び、Ｎａ塩を調製し、ヒト前腕に塗布し血流促進効果を目視にて評価した。サンプルは、（１）ＰＣＡＺｎ塩、（２）ＰＣＡＮａ塩、（３）グルコン酸Ｚｎ塩、（４）グルコン酸Ｎａ塩、（５）硫酸Ｚｎ塩、（６）硫酸Ｎａ２塩を用いた。濃度は５ｗｔ％とし、ｐＨは５．５〜６．５の間に調製した。上記サンプルを８０μｌ、前腕に半閉塞パッチし、３０分後パッチを除去し、目視評価を行った。さらに、３０分後、５０分後に目視観察を行い、表１に従い評点を付した。結果を表２に示す。結果は得られた評点の平均である。
【００４９】
【表１】
【００５０】
【表２】
【００５１】
サンプル（１）及び（２）では一過性の血流促進効果が確認された。しかし、その他のサンプルにおいては、どの評価時間帯においても血流促進効果は認められなかった。この結果から、ＰＣＡＺｎ塩はその他のＺｎ塩に比べ、皮膚に塗布することで一時的な血流促進効果を誘導することが判明した。
これにより、血管内のアスコルビン酸などの有用物質を塗布部位に集めることで、ＰＣＡＺｎ塩はその他のＺｎ塩に比べ、よりコラーゲン産生促進効果を高めることが期待される。
【００５２】
試験例３．ピロリドンカルボン酸亜鉛塩のヒト真皮繊維芽細胞コラーゲン合成促進効果
正常ヒト真皮繊維芽細胞を６ウェルプレートにＤＭＥＭ（ダルベッコ改変イーグル培地、ＦＢＳ１０％含有）にて播種した。５％ＣＯ２、飽和水蒸気下、３７℃のインキュベータで２４時間培養した。２４時間後、サンプル（ＰＣＡ亜鉛塩など）を１０μＭの濃度で添加したＤＭＥＭ（ＦＢＳ１０％含有、アスコルビン酸５００μＭ含有）に、６ウェルプレートの培地を交換した。サンプルの交換は毎日行い、計５回サンプル交換（８日間）を行った。最後のサンプルを交換した後、２４時間後、培地を吸引除去しＰＢＳにてウェルをリンスした。得られたコラーゲンシートを酵素的に分解し可溶化させ、ＥＬＩＳＡにてＩ型コラーゲン量を定量評価した。
図２に示したように、ピロリドンカルボン酸亜鉛塩を１０μＭ添加したＩ型コラーゲン量はコントロール（ピロリドンカルボン酸亜鉛塩無添加）に比べ、１８０％の増加を示した。
【００５３】
試験例４．ピロリドンカルボン酸亜鉛塩のアスコルビン酸トランスポーターｍＲＮＡ発現増強効果
正常ヒト真皮繊維芽細胞をシャーレにＤ−ＭＥＭ（ダルベッコ改変イーグル培地、ＦＢＳ１０％含有）にて播種した。５％ＣＯ２、飽和水蒸気下、３７℃のインキュベータで１日、培養した。シャーレにサンプル（ＰＣＡ亜鉛塩など）を１μＭ、５０μＭの濃度で添加し、インキュベータにて２４時間培養した。培養後、培地を吸引除去し、ＰＢＳでリンスした。細胞はＲＮ ｅａｓｙ Ｍｉｎｉ Ｋｉｔ（Ｑｕｉａｇｅｎ製）のプロトコールに従って、細胞内中のＲＮＡの抽出を行った。得られたＲＮＡから、定法に従いｃ−ＤＮＡを合成し、文献既知の方法にて（Ｃｈｒｉｓｔｏｐｈｅｒ Ｐ．Ｃｏｒｐｅ ｅｔｃ（２００５）Ｊ．Ｂｉｏｌ．Ｃｈｅｍ．２８０、５２１１−５２２０）、アスコルビン酸トランスポーター；ＳＶＣＴのＲＴ−ＰＣＲを行った（プライマー：センスプライマー；５’−ＣＴＧＡＧＣＴＣＡＴＧＧＣＧＡＴＣＴＡＣ−３’（配列番号１）、アンチセンス；５’−ＣＡＴＧＴＣＡＧＧＴＡＧＴＧＣＴＧＴＡＧＣＣＣＣＡ−３’（配列番号２））。得られたＤＮＡを電気泳動し、サンプルの有無によるＳＶＣＴのＲＮＡの発現量を評価した。電気泳動のバンドの評価は、ルミノ・イメージアナライザー（ＬＡＳ−３０００／富士フィルム製）を用い、Ｇ３ＰＤＨにて規格化した数値にて行った。
図３に示すように、ピロリドンカルボン酸亜鉛塩を１μＭ、５０μＭ添加することで、無添加のコントロールに比べ１μＭで１５０％、５０μＭ添加で２００％のアスコルビン酸トランスポーターのＲＮＡ発現量の増加が確認された。これにより、ＮＨＤＦでのアスコルビン酸トランスポーターが増加し細胞内のアスコルビン酸濃度の増加、これに伴いＮＨＤＦのコラーゲン合成量が増加したと考えられる。
【００５４】
試験例５．ピロリドンカルボン酸亜鉛塩とユビキノンのヒト真皮繊維芽細胞コラーゲン合成促進効果
正常ヒト真皮繊維芽細胞を６ウェルプレートにＤ−ＭＥＭ（ダルベッコ改変イーグル培地、ＦＢＳ１０％含有）にて播種した。５％ＣＯ２、飽和水蒸気下、３７℃のインキュベータで２４時間培養した。２４時間後、サンプル（１）ＰＣＡ亜鉛塩（３０μＭ）＋ユビキノン（３０μＭ）、サンプル（２）ＰＣＡ亜鉛塩（３０μＭ）、サンプル（３）ユビキノン（３０μＭ）を添加したＤＭＥＭ（ＦＢＳ１０％含有、アスコルビン酸５００μＭ含有）に、６ウェルプレートの培地を交換した。サンプルの交換は毎日行い、計５回サンプル交換（８日間）を行った。最後のサンプルを交換した後、２４時間後、培地を吸引除去しＰＢＳにてウェルをリンスした。得られたコラーゲンシートを酵素的に分解し可溶化させ、ＥＬＩＳＡにてＩ型コラーゲン量を定量評価した。
図４に示したように、ピロリドンカルボン酸亜鉛塩単独ではコントロール（サンプル無添加）に比べ約３００％のコラーゲンマトリックス生成促進効果を示し、ユビキノン単独では２５０％の促進効果を示した。さらに、ピロリドンカルボン酸亜鉛塩とユビキノンを併用投与した場合、コラーゲン合成促進は約４００％まで上昇し、ピロリドンカルボン酸亜鉛塩単独の場合よりも強いコラーゲン合成促進効果が確認された。
これにより従来知られていなかったユビキノンおよびピロリドンカルボン酸亜鉛塩の組み合わせにコラーゲン合成促進効果があることが示され、さらに、ユビキノンのエネルギー産生促進効果をピロリドンカルボン酸亜鉛塩がコラーゲン合成促進につなげ、両者を併用することで、コラーゲン合成促進を相乗的に増加させることに成功した。
【００５５】
試験例６．ピロリドンカルボン酸亜鉛塩配合処方による三次元培養ヒト皮膚におけるコラーゲン合成促進効果
角層、表皮層、真皮層を持ちコラーゲンマトリックスを形成している三次元培養ヒト皮膚モデルを用い、ＰＣＡ亜鉛塩（０．００１ｗｔ％）、ユビキノン、Ｎ，Ｎ’−ジアセチルシスチンジメチルエステル（ＤＡＣＤＭ）、アミノ酸数種類を配合したクリームＡ（表７および表８を参照）を角層表面に１００μｌ塗布した。さらに、比較対象としてクリームＡから上記４種類（ＰＣＡ亜鉛塩、ユビキノン、ＤＡＣＤＭ、アミノ酸群）を除いたクリームＢを、コントロールとしてはリン酸バッファー（ＰＢＳ）を同様に、それぞれ１００μｌ角層表面に塗布した。皮膚モデルの真皮層側には皮膚モデル用培地を張り、培地は毎日交換した。サンプルを塗布後、皮膚モデルは、５％ＣＯ２、飽和水蒸気下、３７℃のインキュベータにて培養した。サンプル塗布後３日目に、上層のサンプル、下層の培地を取り除き、水でリンス後、皮膚を凍結乾燥した。凍結乾燥後、真皮層のみを水に１日浸潤させた。１日後、浸潤した真皮層を上記試験例２．で行った方法を用い、コラーゲンマトリックスを酵素的に分解可溶化し、ＥＬＩＳＡにてＩ型コラーゲン量を定量評価した。
図５に示すように、ピロリドンカルボン酸亜鉛塩を含んだクリームＡを塗布した三次元培養ヒト皮膚モデルは、コントロール、及びクリームＢに比較し、真皮層のコラーゲンマトリックス中のＩ型コラーゲン量が１７０％程度増加した。
【００５６】
合成例１．ピロリドンカルボン酸亜鉛塩の合成
ＤＬ−ＰＣＡ亜鉛塩は特開平３−１６８２４０号公報記載の方法に準じ、ＤＬ−ＰＣＡと酸化亜鉛を水中１００℃で２時間反応させた後、室温下５時間攪拌を続け、析出した結晶をろ別することにより合成した。Ｌ−ＰＣＡ亜鉛塩は以下の方法で合成した。オートクレーブ中にて、Ｌ−グルタミン酸ナトリウム１水和物（６１．１ｇ）の水溶液を１８０℃で２時間加熱し、５０ｗｔ％のピロリドンカルボン酸ナトリウム塩溶液を得た。５０ｗｔ％のピロリドンカルボン酸ナトリウム塩溶液１００．０ｇ（０．３３ｍｏｌ、ｐＨ７．７、光学純度８４％、Ｌ／Ｄ比率＝９２／８）に、硝酸（純度 ６０ｗｔ％）２．７ｇを添加し、ｐＨ５．２に調整した。硫酸亜鉛７水和物４７．６ｇ（０．１７ｍｏｌ）を水３４．２ｇに溶解した水溶液を、ピロリドンカルボン酸ナトリウム塩溶液（ｐＨ４．１）に添加した。この溶液を３０分間室温（ｐＨ３．７）で結晶を得るまで混和し、ろ過した。得られた結晶は水（２１．９ｇ）で洗浄し、３２．０ｇ（０．０９ｍｏｌ、収率５５％）のピロリドンカルボン酸亜鉛二水和物を得た。光学純度は９９．８％（Ｌ／Ｄ比率９９．９／０．１）であった。
【００５７】
配合例１〜４０
以下に、種々の製剤の配合例を次に示す。これらの製剤は常法に従い調製した。尚、配合量は重量％で表した。
【００５８】
以下に、軟膏の配合例を示す。
【００５９】
【表３】
以下に、化粧水の配合例を示す。
【００６１】
【表４】
【表５】
以下に、ローションの配合例を示す。
【００６４】
【表６】
以下に、クリームの配合例を示す。
【００６６】
【表７】
【表８】
以下に、乳液の配合例を示す。
【００６９】
【表９】
以下に、美容液の配合例を示す。
【００７１】
【表１０】
以下に、パックの配合例を示す。
【００７３】
【表１１】
以下に、ファンデーションの配合例を示す。
【００７５】
【表１２】
以下に、液体ハンドソープの配合例を示す。
【００７７】
【表１３】
以下に、シャンプーの配合例を示す。
【００７９】
【表１４】
以下に、毛髪用化粧水の配合例を示す。
【００８１】
【表１５】
【００８２】
本発明は、化粧品の分野において効果の高いコラーゲン合成促進剤として利用可能である。従来知られていた、レチノイド、レチノール、レチノイン酸と同等以上のコラーゲン合成促進効果があり、催奇性、副作用もなく、より安全なコラーゲン合成促進剤である。
【Technical field】
[0001]
The present invention relates to a collagen synthesis promoter containing zinc as an active ingredient useful for preventing wrinkles, and a composition containing the same.
[Background]
[0002]
Many substances that prevent or improve skin wrinkles have been found, but there are no safe substances that can be completely prevented or improved, and many studies are still being conducted. Various causes of wrinkle formation have been reported, one of which is dry skin. It is a well-known fact that skin wrinkles appear as the amount of water in the stratum corneum decreases. For this reason, a moisturizing component is used to maintain a high amount of moisture in the skin stratum corneum. NMF (Natural Moi) as a moisturizing ingredient in our own skin stratum corneumsturizing factor) is well known, but the amino acid itself, which is a constituent element, has also been found to retain water in the stratum corneum. In addition, proposals have been made to promote the turnover of skin keratinocytes by using cell activation components such as placenta extract and vitamins to prevent and improve wrinkles.
[0003]
As a cause different from dryness, it is considered that a decrease in the amount of collagen in the dermis is related to wrinkles and sagging associated with aging of the skin. Collagen in the skin is a component of the extracellular matrix of the dermis and plays an important role as a connective tissue. Collagen amount is an important factor constituting the softness and tension of the skin.
[0004]
In order to increase the amount of collagen in the skin tissue, it is important to inhibit collagenase activity induced by UV irradiation, suppress collagen degradation, and promote collagen synthesis. It is known that collagen synthesis is promoted by the action of vitamins, hormones, cytokines and the like.
[0005]
Collagen proteins and collagen composition amino acid compositions are commercially available as products that promote collagen synthesis, but the effect of promoting collagen synthesis is not clear.
[0006]
Retinoids, retinol, and retinoic acid are known to promote collagen synthesis, but teratogenicity and side effects have been reported, and a safer and more effective collagen synthesis promoter is required.
[0007]
Ubiquinone is a compound isolated and discovered from intracellular mitochondria of bovine heart in 1957 and is also called coenzyme Q10, coenzyme Q10, or simply CoQ10. Ubiquinone is produced in the body and is present in many organs. One of its functions is the production of energy in intracellular mitochondria. In the mitochondria, high-energy molecules such as ATP are produced through the electron transport system and the TCA cycle using sugars and lipids. That is, ubiquinone works in the electron transport system and contributes to ATP production. The amount of ubiquinone in the heart is said to be reduced to about half of that at the age of 20 after 40 years of age. In the skin, there are still few detailed data on ubiquinone, but as with other organs, the concentration of ubiquinone is thought to decrease with age.
[0008]
Another function of ubiquinone is an antioxidant effect. Since skin is often exposed to ultraviolet rays and the like, an oxidation reaction in the skin is always caused. In order to prevent this oxidation reaction, it is considered that many ubiquinones are produced and used. In 2004, ubiquinone became available as a cosmetic product, and it has come to be used in many cosmetics. However, in addition to promoting skin turnover by promoting energy production and antioxidative effects, ubiquinone is specific to the skin. There are still many unclear points about the positive effects.
[0009]
On the other hand, regarding zinc, zinc oxide, which is a kind of inorganic zinc salt, has been reported to suppress diaper rash (for example, FEBS Letters, 384, 92-96, 1996). However, this compound is hardly soluble in water and oily components and is difficult to use as a component in cosmetics and skin external preparations.
[0010]
It is known that glycine zinc salt which is a kind of organic zinc salt has a metallothionein induction promoting action (Japanese Patent Laid-Open No. 2005-247729). This is an action of suppressing skin damage caused by UV, such as inhibition of melanin synthesis and inhibition of cytotoxicity, through pathways such as an antioxidant effect and radical scavenging ability. However, the effect of glycine zinc salt on collagen synthesis is not known.
[0011]
Similarly, pyrrolidone carboxylic acid zinc salt and acylamino acid zinc salt, which are also one of organic zinc salts, are known to suppress UV-induced inflammatory factors such as AP-1 and NF-κB (JP 2006-2006 A). No. 022090, International Publication WO2005 / 123062 Pamphlet). However, the action of pyrrolidone carboxylic acid zinc salt and acylamino acid zinc salt on collagen synthesis is not known.
[0012]
In addition, organic zinc salts and inorganic zinc salts are known to be incorporated into cosmetic compositions for astringent, anti-inflammatory, white pigment, UV protection, deodorant and bactericidal agents, but expected to be effective Use in the vicinity of the concentration range where it can be made is difficult to use as a cosmetic because of irritation to the skin. Moreover, in the utilization at low concentration, the above-mentioned effectiveness to the skin is not found, and the present condition is that the blending of zinc salts into cosmetics has not progressed.
DISCLOSURE OF THE INVENTION
[0013]
As a result of intensive studies aimed at improving wrinkles by collagen synthesis rather than moisturizing and improving wrinkles by promoting skin turnover, the present inventors have introduced zinc into human dermal fibroblasts. The present inventors have found that it has an effect of promoting the expression of ascorbic acid transporter, and accordingly, it has been found that an effect of promoting collagen synthesis can be obtained.
[0014]
Ascorbate transporters are membrane proteins that promote the uptake of ascorbate into cells (see Hiroya Tsukaguchi etc (1999) Nature 399, 70-75).,By enhancing the expression of the ascorbic acid transporter, the uptake of ascorbic acid essential for collagen synthesis in dermal fibroblasts is increased, and collagen synthesis is promoted.
[0015]
Furthermore, surprisingly, collagen synthesis is synergistically promoted remarkably by adding pyrrolidonecarboxylic acid zinc salt, which is one of zinc salts, to ubiquinone, which has not been known to promote collagen synthesis. I found out.
[0016]
An object of the present invention is to obtain a collagen synthesis accelerator having an excellent collagen synthesis action and a cosmetic composition containing the same based on the above findings.
[Means for Solving the Problems]
[0017]
That is, the present invention comprises a composition for promoting collagen synthesis characterized by containing zinc as an active ingredient, and a composition for promoting collagen synthesis characterized by comprising ubiquinone and zinc pyrrolidonecarboxylic acid as active ingredients. About.
[0018]
From the viewpoint of skin irritation, introduction efficiency into cells, etc., as a practical zinc introduction method, it is necessary to make zinc a zinc salt and apply it to the skin at a certain concentration. Includes the following inventions.
[0019]
(1) A collagen synthesis promoter containing zinc as an active ingredient.
(2) Zinc is pyrrolidone carboxylic acid zinc salt, gluconic acid zinc salt,Zinc phenol sulfonateThe collagen synthesis promoter according to (1), which is a compound selected from the group consisting of zinc lactate, various amino acid zinc salts, acylamino acid zinc salts, zinc sulfate, zinc chloride and zinc oxide.
(3) The collagen synthesis promoter according to (1), wherein the zinc is pyrrolidone carboxylic acid zinc salt.
(4) Collagen synthesis promoter containing pyrrolidone carboxylic acid zinc salt and ubiquinone as active ingredients.
(5) The collagen synthesis promoter according to (1) to (4), wherein the collagen synthesis is performed through enhanced expression of an ascorbate transporter of human fibroblasts.
(6) A composition for promoting collagen synthesis, characterized by containing zinc as an active ingredient.
(7) Zinc is pyrrolidone carboxylic acid zinc salt, gluconic acid zinc salt,Zinc phenol sulfonateThe composition for promoting collagen synthesis according to (6), which is a compound selected from the group consisting of zinc lactate, various amino acid zinc salts, acylamino acid zinc salts, zinc sulfate, zinc chloride and zinc oxide.
(8) The composition for promoting collagen synthesis according to (6), wherein the zinc is a pyrrolidone carboxylic acid zinc salt.
(9) A composition for promoting collagen synthesis, comprising zinc pyrrolidonecarboxylic acid and ubiquinone as active ingredients.
(10) The composition for promoting collagen synthesis according to (6) to (9) above, wherein zinc is blended so as to be present in the composition at a concentration of 1 μM to 100 mM.
(11) The composition for promoting collagen synthesis according to (6) to (10) above, further comprising an N-acyl acidic amino acid ester or an amino acid derivative.
(12) The composition for promoting collagen synthesis according to the above (6) to (11), which is an ointment, lotion, lotion, cream, milky lotion, serum, pack, foundation, liquid hand soap, shampoo, or hair lotion. object.
(13) A preventive or therapeutic agent for wrinkles, characterized by containing zinc as an active ingredient.
(14) Zinc is pyrrolidone carboxylic acid zinc salt, gluconic acid zinc salt,Zinc phenol sulfonateThe wrinkle preventive or therapeutic agent according to (13), which is a compound selected from the group consisting of zinc lactate, various amino acid zinc salts, acylamino acid zinc salts, zinc sulfate, zinc chloride and zinc oxide.
(15) The wrinkle preventive or therapeutic agent according to (13), wherein the zinc is a pyrrolidone carboxylic acid zinc salt.
(16) A prophylactic or therapeutic agent for wrinkles characterized by comprising pyrrolidonecarboxylic acid zinc salt and ubiquinone as active ingredients.
(17) Use of zinc for promoting collagen synthesis.
(18) pyrrolidone carboxylic acid zinc salt, gluconate zinc salt for promoting collagen synthesis,Zinc phenol sulfonateUse of a zinc salt selected from the group consisting of zinc lactate, various amino acid zinc salts, acylamino acid zinc salts, zinc sulfate, zinc chloride and zinc oxide.
(19) Use of pyrrolidone carboxylic acid zinc salt for promoting collagen synthesis.
(20) A combination of pyrrolidone carboxylic acid zinc salt and ubiquinone for promoting collagen synthesis.
(21) A method for promoting collagen synthesis, comprising applying the composition according to (6) to (12) to the skin.
(22) The collagen synthesis promoter according to (4) above, wherein ubiquinone and pyrrolidonecarboxylic acid zinc salt are contained in a weight ratio of 50: 1 to 0.1: 1.
(23) A composition for promoting collagen synthesis, comprising 0.0001 wt% to 10 wt% ubiquinone and 0.000035 wt% to 3.5 wt% pyrrolidone carboxylic acid zinc salt.
(24) A wrinkle preventive or therapeutic agent comprising 0.0001 wt% to 10 wt% ubiquinone and 0.000035 wt% to 3.5 wt% pyrrolidone carboxylic acid zinc salt.
(25) Promoting collagen synthesis characterized by applying to the skin a composition containing 0.0001 wt% to 10 wt% ubiquinone and 0.000035 wt% to 3.5 wt% pyrrolidone carboxylic acid zinc salt Method.
[Brief description of the drawings]
[0020]
FIG. 1 is a diagram confirming the collagen synthesis promoting effect of zinc salt using human dermal fibroblasts.
FIG. 2 is a diagram confirming the collagen synthesis promoting effect of pyrrolidone carboxylic acid zinc salt using human dermal fibroblasts.
FIG. 3 is a diagram confirming the ascorbic acid transporter mRNA expression enhancing effect by pyrrolidone carboxylic acid zinc salt.
FIG. 4 is a diagram confirming the collagen synthesis promoting effect by pyrrolidone carboxylic acid zinc salt and ubiquinone using human dermal fibroblasts.
FIG. 5 is a diagram in which the effect of promoting collagen synthesis in three-dimensional cultured human skin by the prescription of pyrrolidone carboxylic acid zinc salt is confirmed.
DETAILED DESCRIPTION OF THE INVENTION
BEST MODE FOR CARRYING OUT THE INVENTION
[0021]
Details of the present invention will be described below.
[0022]
Zinc used in the present invention needs to be applied to the skin at a constant concentration in the form of zinc salt as a realistic zinc salt from the viewpoint of skin irritation and cell introduction efficiency. In this case, both an organic zinc salt and an inorganic zinc salt can be used. Organic zinc salts include pyrrolidone carboxylic acid zinc salt, gluconic acid zinc salt,Zinc phenol sulfonateZinc lactate, various amino acid zinc salts, acylamino acid zinc salts, and the like. Inorganic zinc salts include zinc sulfate, zinc chloride, zinc oxide and the like.
[0023]
As amino acid zinc salt, glycine zinc salt, alanine zinc salt, valine zinc salt, leucine zinc salt, isoleucine zinc salt, phenylalanine zinc salt, methionine zinc salt, tryptophan zinc salt, asparagine zinc salt, glutamine zinc salt, serine zinc salt, Examples include various amino acid zinc salts such as threonine zinc salt, cysteine zinc salt, tyrosine zinc salt, zinc aspartate, zinc glutamate, lysine zinc, arginine zinc, or histidine zinc.
[0024]
The acylamino acid zinc salt is a zinc salt of a compound in which an acyl group is bonded to the amino group of the amino acid, and examples of the acylamino acid include compounds having the following structural formula.
[0025]
[Chemical 1]
[0026]
(In the above (I), R1 is an acyl group having 2 to 22 carbon atoms, R2 is a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms, R3 is an amino acid such as valine, leucine, or isoleucine. , Phenylalanine, methionine, tryptophan, asparagine, glutamine, serine, threonine, cysteine, tyrosine, aspartic acid, glutamic acid, lysine, arginine, histidine, alanine or a hydrogen atom, n represents an integer of 0 or 1 .)
[0027]
In terms of enhancing collagen synthesis promoting effect, pyrrolidone carboxylic acid zinc salt, which has blood flow promoting effect, is expected to collect useful substances such as ascorbic acid in blood vessels at the application site. It is a zinc salt whose expression promoting effect is more remarkably reflected in the collagen synthesis promoting effect.
[0028]
The pyrrolidone carboxylic acid zinc salt (hereinafter also referred to as PCA zinc salt or PCAZn salt) is a zinc salt of 2-pyrrolidone-5-carboxylic acid, and may be various hydrates. The pyrrolidone carboxylic acid zinc salt used in the examples is a dihydrate and has the following structure.
[0029]
[Chemical 2]
[0030]
As the pyrrolidone carboxylic acid zinc salt, any of D-form, L-form and DL-form (mixture of D-form and L-form) may be used. For example, L-PCA zinc salt or DL-PCA zinc salt can be used. These can be used alone or in combination. When a DL form is used, the ratio of the D form and the L form is not particularly limited.
[0031]
The collagen synthesis promoter of the present invention is used by being blended in a composition such as a cosmetic or a skin external preparation. At this time, the blending amount is 1 μM to 100 mM (0.000035 wt% to 3.5 wt% as PCA zinc salt), preferably 1 μM to 10 mM (0.000035 wt% to 0.35 wt% as PCA zinc salt). More preferably, it is important to add a very small amount of about 1 μM to 1 mM (0.000035 wt% to 0.035 wt% as PCA zinc salt). When the blending amount is 3.5% by weight or more, there is a problem that the skin is irritated or a squeaky sensation is produced. Does not occur and is not preferable.
[0032]
When the collagen synthesis promoter of the present invention is blended in a composition such as a cosmetic or a skin external preparation, in addition to these components, a component that is generally used as a cosmetic or a skin external preparation does not inhibit the effects of the present invention. Can be added.
[0033]
The second aspect of the present invention relates to a collagen synthesis accelerator containing ubiquinone and pyrrolidone carboxylic acid zinc salt as active ingredients. As explained so far, pyrrolidone carboxylic acid zinc salt can be used alone as a collagen synthesis promoter, but when used in combination with ubiquinone, it can be used as a collagen synthesis promoter having a surprising synergistic effect. it can. Thereby, the improvement of wrinkles by collagen synthesis can be expected, not the improvement of wrinkles due to the promotion of skin turnover and the antioxidant effect.
[0034]
In the present invention, ubiquinone is a ubiquinone in which the side chain isoprene unit of 2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-benzoquinone is 10, in order to appropriately express the effects of the present invention. The amount of ubiquinone is preferably 0.0001% by weight or more, more preferably 0.01% by weight or more, and still more preferably 0.03% by weight or more. Further, if the blending amount of ubiquinone is increased more than necessary, it may be crystallized or the color of the product may be yellowed, so it is preferably 10% by weight or less, more preferably 1% by weight or less, More preferably, the content is 0.1% by weight or less. In order for the pyrrolidone carboxylic acid zinc salt to express its effect appropriately, the blending ratio of ubiquinone and pyrrolidone carboxylic acid zinc salt is contained in a ratio of 50: 1 to 0.1: 1.RuIt is preferable.
[0035]
Further, as a further aspect of the present invention, a composition comprising the collagen synthesis promoter of the present invention and one or more selected from the group consisting of N-acyl acidic amino acid esters, amino acids and amino acid derivatives, at the same time. Related to things.
[0036]
The N-acyl acidic amino acid ester that can be blended in the composition of the present invention is represented by the following structure:
[0037]
[Chemical 3]
[0038]
(Wherein X and Y may be the same or different, X and Y are ester-forming residues of sterols, linear or branched liquid higher alkyl alcohols or alkenyl alcohols having 8 to 30 carbon atoms, or It is at least one selected from ester-forming residues of solid linear or branched higher alcohols having 12 to 38 carbon atoms, and COR bonded to the nitrogen atom is a linear acyl group having 8 to 22 carbon atoms. N is 1 or 2. a and b are 0 to 10, and b is 0 to 10.)
[0039]
N-acyl acidic diesters are particularly preferred, and suitable examples thereof include, for example, N-lauroyl glutamate di (cholesteryl behenyl octyldodecyl), N-lauroyl glutamate di (cholesteryl octyldodecyl), N-lauroyl glutamate di (phytosteryl 2) -Octyl dodecyl), N-lauroyl glutamate di (octyl dodecyl phytosteryl behenyl), and the like, which are available from Ajinomoto Co., Inc., respectively, "El Deu CL-301", "El Deu CL-202", "El Deu PS -203 "and" El Dew PS-304 ".
[0040]
And in this invention, this N-acyl acidic amino acid ester contributes to the improvement of moisture retention and skin conditioning, and also contributes to the improvement of stability. The blending amount is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, further preferably 0.5% by weight or more, and an N-acyl acidic amino acid. If the blending amount of the ester is increased more than necessary, it may become sticky. Therefore, the amount is preferably 20% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less.
[0041]
An amino acid or an amino acid derivative is included in the composition to contribute to the improvement of the moisturizing effect. Examples of the amino acid include alanine, arginine, asparagine, aspartic acid, citrulline, cysteine, cystine, glutamine, glutamic acid, Glycine, histidine, oxyproline, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, etc., and any of those L, D or DL forms It may also be a salt thereof. Examples of such salts include sodium salt, potassium salt, triethanolamine salt and the like.
[0042]
Examples of amino acid derivatives include those obtained by cyclization, acylation or esterification of the above-mentioned amino acids, such as acetyl glutamic acid, acetyl methionine, acetyl cysteine, N, N-diacetyl-L-cystine dimethyl ester, acyl glutamic acid. Salts, acylglycine salts, acylalanine salts, acylarginine ethyl ester salts, and the like. However, N-acyl acidic amino acid ester is not included.
[0043]
Ingredients commonly used in cosmetics or external preparations for skin include antioxidants, anti-inflammatory agents, UV absorbers, whitening agents, cell activators, moisturizers, metal chelating agents, oily raw materials, surfactants, solvents , Polymer substances, powder substances, pigments, fragrances, transdermal absorption enhancers and steroid hormones.
[0044]
There is no restriction | limiting in particular in the form of the composition containing the said zinc salt, Arbitrary forms, such as solution form, paste form, gel form, solid form, powder form, can be taken. Further, the composition of the present invention comprises oil, lotion, cream, emulsion, gel, shampoo, hair rinse, hair conditioner, enamel, foundation, lipstick, funny, pack, ointment, tablet, injection solution, granule, capsule, perfume, Powder, eau de cologne, toothpaste, soap, aerosol, cleansing foam, etc., skin aging prevention improver, skin inflammation prevention improver, bath preparation, hair nourishing agent, skin beauty solution, sunscreen agent, xeroderma pigmentosum / Nikko urticaria Photosensitivity prevention and improvement agent, photoallergy prevention improvement agent, photoimmune suppression prevention improvement agent or skin roughening prevention and improvement agent such as trauma, scuffing and cracking, disinfectant, antibacterial agent, insecticide, pest control Agent, keratolytic agent, epidermis remover, acne prevention / amelioration agent, prevention of various skin diseases such as keratosis, psoriasis, ichthyosis and psoriasis It can be used to good agent.
[0045]
Furthermore, other commonly used components can be added to the composition as long as the effects of the present invention are not impaired. Other commonly used ingredients in the composition of the present invention include antiseptics, anti-fading agents, buffers, acne agents, anti-dandruff and itching agents, antiperspirant deodorants, burn agents, anti-ticks and lice agents, keratin softening , Agents for xeroderma, antiviral agents, hormones, vitamins, amino acids / peptides, proteins, astringents, refreshing / stimulating agents, animal and plant derived components, antibiotics, antifungal agents, hair restorers, etc. be able to.
【Example】
[0046]
EXAMPLES Hereinafter, although an Example (synthesis example, a test example, and a compounding example) demonstrates this invention further more concretely, this invention is not limited to these Examples. In these examples, the blending amount was expressed in wt%.
[0047]
Test Example 1 Collagen synthesis promoting effect of zinc salt
In order to confirm the collagen synthesis promoting effect of the zinc salt, two types of zinc salt and the same sodium salt were prepared, and the collagen synthesis promoting effect from normal human dermal fibroblasts was evaluated. Normal human dermal fibroblasts in a confluent state are peeled off, seeded in a 96-well plate in D-MEM (containing 10% FBS), and subjected to saturated water vapor at 37 ° C., 5% CO for 24 hours.2And aseptically cultured. After 24 hours, the medium was removed, and each sample was added with D-MEM prepared to a predetermined concentration (50 μM, containing 250 μM sodium ascorbate and 2% FBS). 48 hours under saturated steam at 37 ° C, 5% CO2And aseptically cultured. After 48 hours, the culture supernatant was collected, and the amount of type I procollagen released from human dermal fibroblasts in the liquid was quantitatively evaluated by ELISA.
The results are shown in FIG. As can be seen from the graph, both types of zinc salts increased the amount of collagen synthesized in the medium in 48 hours compared to the control. However, the corresponding sodium salt did not increase the amount of collagen synthesis in the medium.
[0048]
Test Example 2 Effect of PCAZn salt on blood flow
The difference between PCAZn salt and other Zn salt was confirmed from the blood flow promoting effect (blood volume increase). The Zn salt and Na salt of each sample were prepared and applied to a human forearm to visually evaluate the blood flow promoting effect. sample,(1)PCAZn salt,(2)PCANA salt,(3)Zn gluconate,(4)Gluconic acid Na salt,(5)Zn sulfate,(6)Na sulfate2Salt was used. The concentration was 5 wt%, and the pH was adjusted between 5.5 and 6.5. 80 μl of the sample was semi-occluded patched on the forearm, 30 minutes later, the patch was removed, and visual evaluation was performed. Further, visual observation was performed after 30 minutes and after 50 minutes, and a score was assigned according to Table 1. The results are shown in Table 2. The result is the average of the scores obtained.
[0049]
[Table 1]
[0050]
[Table 2]
[0051]
sample(1)as well as(2)Then, a transient blood flow promoting effect was confirmed. However, in the other samples, the blood flow promoting effect was not observed in any evaluation time zone. From this result, it was found that the PCAZn salt induces a temporary blood flow promoting effect when applied to the skin as compared with other Zn salts.
As a result, by collecting useful substances such as ascorbic acid in blood vessels at the application site, the PCAZn salt is expected to enhance the collagen production promoting effect more than other Zn salts.
[0052]
Test Example 3 Effect of zinc pyrrolidonecarboxylate on the synthesis of human dermal fibroblast collagen
Normal human dermal fibroblasts were seeded in 6-well plates with DMEM (Dulbecco's modified Eagle medium, containing 10% FBS). 5% CO2The cells were cultured in a 37 ° C. incubator under saturated steam for 24 hours. After 24 hours, the medium of the 6-well plate was replaced with DMEM (containing 10% FBS and containing 500 μM ascorbic acid) to which a sample (PCA zinc salt or the like) was added at a concentration of 10 μM. Samples were exchanged every day, for a total of 5 sample exchanges (8 days). After changing the last sample, 24 hours later, the medium was removed by suction and the wells were rinsed with PBS. The obtained collagen sheet was enzymatically decomposed and solubilized, and the amount of type I collagen was quantitatively evaluated by ELISA.
As shown in FIG. 2, the amount of type I collagen to which 10 μM of pyrrolidone carboxylic acid zinc salt was added showed an increase of 180% compared to the control (no addition of pyrrolidone carboxylic acid zinc salt).
[0053]
Test Example 4 Ascorbic acid transporter mRNA expression enhancing effect of pyrrolidone carboxylic acid zinc salt
Normal human dermal fibroblasts were seeded in a petri dish with D-MEM (Dulbecco's modified Eagle medium, containing 10% FBS). 5% CO2Then, the cells were cultured in a 37 ° C. incubator under saturated steam for 1 day. A sample (PCA zinc salt or the like) was added to the petri dish at a concentration of 1 μM or 50 μM and cultured in an incubator for 24 hours. After culturing, the medium was removed by suction and rinsed with PBS. The cells were extracted with RNA in the cells according to the protocol of RN easy Mini Kit (manufactured by Qiagen). From the obtained RNA, c-DNA was synthesized according to a conventional method, and a method known in the literature (Christopher P. Corp et c (2005) J. Biol. Chem. 280, 5211-5220), ascorbic acid transporter; SVCT RT-PCR was performed (primer: sense primer; 5'-CTGAGCTCATGGCGATTAC-3 '(SEQ ID NO: 1), antisense; 5'-CATGTCAGGTAGTGCTGTTAGCCCCA-3' (SEQ ID NO: 2)). The obtained DNA was electrophoresed to evaluate the expression level of SVCT RNA depending on the presence or absence of the sample. The evaluation of the band of electrophoresis was performed using a numerical value standardized by G3PDH using a lumino image analyzer (LAS-3000 / manufactured by Fuji Film).
As shown in FIG. 3, the addition of 1 μM and 50 μM pyrrolidone carboxylic acid zinc salt confirms an increase in RNA expression level of ascorbic acid transporter by 150% at 1 μM and 200% by addition of 50 μM compared to the control without addition. It was done. As a result, the ascorbic acid transporter in NHDF was increased, the intracellular ascorbic acid concentration was increased, and the collagen synthesis amount of NHDF was increased accordingly.
[0054]
Test Example 5. Effects of zinc pyrrolidonecarboxylate and ubiquinone on human dermal fibroblast collagen synthesis
Normal human dermal fibroblasts were seeded in 6-well plates with D-MEM (Dulbecco's modified Eagle medium, containing 10% FBS). 5% CO2The cells were cultured in a 37 ° C. incubator under saturated steam for 24 hours. 24 hours later, DMEM (containing 10% FBS, ascorbic acid) to which sample (1) PCA zinc salt (30 μM) + ubiquinone (30 μM), sample (2) PCA zinc salt (30 μM), sample (3) ubiquinone (30 μM) was added 6-well plate medium was changed to 500 μM). Samples were exchanged every day, for a total of 5 sample exchanges (8 days). After changing the last sample, 24 hours later, the medium was removed by suction and the wells were rinsed with PBS. The obtained collagen sheet was enzymatically decomposed and solubilized, and the amount of type I collagen was quantitatively evaluated by ELISA.
As shown in FIG. 4, the pyrrolidone carboxylic acid zinc salt alone showed about 300% collagen matrix formation promoting effect compared to the control (no sample added), and ubiquinone alone showed 250% promoting effect. Furthermore, when the pyrrolidone carboxylic acid zinc salt and ubiquinone were administered in combination, the collagen synthesis promotion increased to about 400%, confirming a stronger collagen synthesis accelerating effect than that of the pyrrolidone carboxylic acid zinc salt alone.
This shows that the combination of ubiquinone and pyrrolidone carboxylic acid zinc salt, which has not been known so far, has an effect of promoting collagen synthesis, and further, pyrrolidone carboxylic acid zinc salt leads to the promotion of collagen synthesis by promoting the energy production promoting effect of ubiquinone, By using both together, we succeeded in synergistically increasing collagen synthesis promotion.
[0055]
Test Example 6. Collagen synthesis promotion effect in three-dimensional cultured human skin by formulation containing pyrrolidone carboxylic acid zinc salt
PCA zinc salt (0.001 wt%), ubiquinone, N, N'-diacetylcystine dimethyl ester (DACDM) using a three-dimensional cultured human skin model that has a stratum corneum, epidermis layer and dermis layer to form a
As shown in FIG. 5, the three-dimensional cultured human skin model coated with cream A containing pyrrolidone carboxylic acid zinc salt has 170 type I collagen in the collagen matrix of the dermis layer compared to control and cream B. Increased by about%.
[0056]
Synthesis Example 1 Synthesis of pyrrolidone carboxylic acid zinc salt
DL-PCA zinc salt was prepared by reacting DL-PCA and zinc oxide in water at 100 ° C. for 2 hours in accordance with the method described in JP-A-3-168240, followed by stirring at room temperature for 5 hours. It was synthesized by separating. L-PCA zinc salt was synthesized by the following method. In an autoclave, an aqueous solution of sodium L-glutamate monohydrate (61.1 g) was heated at 180 ° C. for 2 hours to obtain a 50 wt% pyrrolidonecarboxylic acid sodium salt solution. To 100.0 g (0.33 mol, pH 7.7, optical purity 84%, L / D ratio = 92/8) of 50 wt% pyrrolidone carboxylic acid sodium salt solution, 2.7 g of nitric acid (
[0057]
Formulation Examples 1-40
Below, the compounding example of various preparations is shown below. These preparations were prepared according to a conventional method. In addition, the compounding quantity was represented by weight%.
[0058]
Below, the compounding example of an ointment is shown.
[0059]
[Table 3]
Below, the example of a lotion is shown.
[0061]
[Table 4]
[Table 5]
Below, the formulation example of a lotion is shown.
[0064]
[Table 6]
Below, the compounding example of a cream is shown.
[0066]
[Table 7]
[Table 8]
Below, the compounding example of an emulsion is shown.
[0069]
[Table 9]
Below, the formulation example of a cosmetic liquid is shown.
[0071]
[Table 10]
Below, the formulation example of a pack is shown.
[0073]
[Table 11]
Below, the compounding example of a foundation is shown.
[0075]
[Table 12]
Below, the formulation example of a liquid hand soap is shown.
[0077]
[Table 13]
Below, the example of a shampoo is shown.
[0079]
[Table 14]
Below, the formulation example of the skin lotion for hair is shown.
[0081]
[Table 15]
[0082]
INDUSTRIAL APPLICABILITY The present invention can be used as a collagen synthesis promoter that is highly effective in the cosmetic field. It has a collagen synthesis promoting effect equivalent to or better than that of conventionally known retinoids, retinol and retinoic acid, and is a safer collagen synthesis promoter without teratogenicity and side effects.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008522615A JP5423002B2 (en) | 2006-06-23 | 2007-06-21 | Collagen synthesis promoter containing zinc as an active ingredient |
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006173918 | 2006-06-23 | ||
| JP2006173918 | 2006-06-23 | ||
| JP2006223941 | 2006-08-21 | ||
| JP2006223941 | 2006-08-21 | ||
| US86650306P | 2006-11-20 | 2006-11-20 | |
| US86649906P | 2006-11-20 | 2006-11-20 | |
| US60/866,503 | 2006-11-20 | ||
| US60/866,499 | 2006-11-20 | ||
| JP2006329172 | 2006-12-06 | ||
| JP2006329172 | 2006-12-06 | ||
| US87184506P | 2006-12-26 | 2006-12-26 | |
| US60/871,845 | 2006-12-26 | ||
| JP2008522615A JP5423002B2 (en) | 2006-06-23 | 2007-06-21 | Collagen synthesis promoter containing zinc as an active ingredient |
| PCT/JP2007/062958 WO2007148831A1 (en) | 2006-06-23 | 2007-06-21 | Collagen synthesis promoter containing zinc as the active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2007148831A1 JPWO2007148831A1 (en) | 2009-11-19 |
| JP5423002B2 true JP5423002B2 (en) | 2014-02-19 |
Family
ID=44766892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522615A Active JP5423002B2 (en) | 2006-06-23 | 2007-06-21 | Collagen synthesis promoter containing zinc as an active ingredient |
| JP2008522638A Active JP5552741B2 (en) | 2006-06-23 | 2007-06-21 | Whitening agent containing zinc as an active ingredient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522638A Active JP5552741B2 (en) | 2006-06-23 | 2007-06-21 | Whitening agent containing zinc as an active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP5423002B2 (en) |
| TW (2) | TW200808717A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9782336B2 (en) | 2014-09-10 | 2017-10-10 | Ajinomoto Co., Inc. | Moisturizer and cosmetic containing same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113491654A (en) * | 2020-04-07 | 2021-10-12 | 美特瑞生物科技(上海)有限公司 | Formula of whitening skin care product |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58180410A (en) * | 1982-04-16 | 1983-10-21 | Shiseido Co Ltd | Cosmetic |
| JPH06211641A (en) * | 1992-10-26 | 1994-08-02 | Jouvance Daniel | Cosmetic product having stable oxidation-reduction potential |
| JPH09510725A (en) * | 1994-03-25 | 1997-10-28 | バイヤースドルフ・アクチエンゲゼルシヤフト | Active substances and compositions for the treatment of senile dry skin |
| JPH11189522A (en) * | 1997-12-25 | 1999-07-13 | Ajinomoto Co Inc | Cosmetic and skin preparation for external use |
| JP2000355516A (en) * | 1999-06-14 | 2000-12-26 | Ajinomoto Co Inc | New composition for cosmetic |
| JP2001508809A (en) * | 1997-12-17 | 2001-07-03 | カラー アクセス，インコーポレイティド | New antioxidant mixture |
| JP2002212049A (en) * | 2001-01-18 | 2002-07-31 | Noevir Co Ltd | Skin cosmetic |
| JP2002322049A (en) * | 2001-03-23 | 2002-11-08 | L'oreal Sa | Composition for skin containing fiber and ubiquinone |
| JP2003277219A (en) * | 2002-03-20 | 2003-10-02 | Sukoyaka Shokuhin Kk | Process for enhancing improving effects of cosmetic vegetable oil and cream on skin condition such as improving effects on wrinkle and pigmented spot and enhancing effects on senile wart and mole |
| JP2005247729A (en) * | 2004-03-03 | 2005-09-15 | Nikko Chemical Co Ltd | Cosmetic and external preparation for skin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW233264B (en) * | 1992-02-03 | 1994-11-01 | Otsuka Pharma Co Ltd | |
| JP3523009B2 (en) * | 1996-03-15 | 2004-04-26 | 株式会社資生堂 | Aqueous thickened gel composition and liquid oil-in-water emulsion composition |
| JP4841075B2 (en) * | 2000-09-22 | 2011-12-21 | 旭化成ケミカルズ株式会社 | Whitening cosmetics |
| JP4497853B2 (en) * | 2003-07-04 | 2010-07-07 | 株式会社ノエビア | Topical skin preparation |
| JP2006022090A (en) * | 2004-06-08 | 2006-01-26 | Ajinomoto Co Inc | Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt |
| JP3747053B2 (en) * | 2005-07-12 | 2006-02-22 | 株式会社ノエビア | External preparation for skin and method for penetration of whitening agent using the same |
-
2007
- 2007-06-21 TW TW96122286A patent/TW200808717A/en unknown
- 2007-06-21 JP JP2008522615A patent/JP5423002B2/en active Active
- 2007-06-21 JP JP2008522638A patent/JP5552741B2/en active Active
- 2007-06-21 TW TW96122284A patent/TW200808365A/en unknown
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58180410A (en) * | 1982-04-16 | 1983-10-21 | Shiseido Co Ltd | Cosmetic |
| JPH06211641A (en) * | 1992-10-26 | 1994-08-02 | Jouvance Daniel | Cosmetic product having stable oxidation-reduction potential |
| JPH09510725A (en) * | 1994-03-25 | 1997-10-28 | バイヤースドルフ・アクチエンゲゼルシヤフト | Active substances and compositions for the treatment of senile dry skin |
| JP2001508809A (en) * | 1997-12-17 | 2001-07-03 | カラー アクセス，インコーポレイティド | New antioxidant mixture |
| JPH11189522A (en) * | 1997-12-25 | 1999-07-13 | Ajinomoto Co Inc | Cosmetic and skin preparation for external use |
| JP2000355516A (en) * | 1999-06-14 | 2000-12-26 | Ajinomoto Co Inc | New composition for cosmetic |
| JP2002212049A (en) * | 2001-01-18 | 2002-07-31 | Noevir Co Ltd | Skin cosmetic |
| JP2002322049A (en) * | 2001-03-23 | 2002-11-08 | L'oreal Sa | Composition for skin containing fiber and ubiquinone |
| JP2003277219A (en) * | 2002-03-20 | 2003-10-02 | Sukoyaka Shokuhin Kk | Process for enhancing improving effects of cosmetic vegetable oil and cream on skin condition such as improving effects on wrinkle and pigmented spot and enhancing effects on senile wart and mole |
| JP2005247729A (en) * | 2004-03-03 | 2005-09-15 | Nikko Chemical Co Ltd | Cosmetic and external preparation for skin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9782336B2 (en) | 2014-09-10 | 2017-10-10 | Ajinomoto Co., Inc. | Moisturizer and cosmetic containing same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2007148831A1 (en) | 2009-11-19 |
| TW200808365A (en) | 2008-02-16 |
| JPWO2007148832A1 (en) | 2009-11-19 |
| JP5552741B2 (en) | 2014-07-16 |
| TW200808717A (en) | 2008-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2421262T3 (en) | Composition for personal and cosmetic care containing tetrapeptides with CX1X2G, PX1X2P or PX1X2K units | |
| WO2007148831A1 (en) | Collagen synthesis promoter containing zinc as the active ingredient | |
| US20060120980A1 (en) | Novel dermatological composition using bio-activating organocatalysts | |
| EP2555743B1 (en) | Cosmetic use of geranylgeranyl-2-propanol | |
| JP4950571B2 (en) | Composition having ability to promote collagen production | |
| US11045471B2 (en) | Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant | |
| JPH0532533A (en) | Cosmetic | |
| JP5423002B2 (en) | Collagen synthesis promoter containing zinc as an active ingredient | |
| JP2006022090A (en) | Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt | |
| JP5455292B2 (en) | Skin external composition | |
| JP6858837B2 (en) | N-lipo amino acids or peptides, derivatives and their use | |
| WO2000064926A1 (en) | Melanocyte-stimulating hormone inhibitors | |
| JP6741014B2 (en) | Moisturizer and cosmetics containing the same | |
| US20220127242A1 (en) | N-lipoic-amino acid or peptide, derivatives and their uses | |
| FR2968952A1 (en) | N-ACYL AMINO ACID ESTER AS A SOOTHING AGENT | |
| JP2005239698A (en) | Skin care preparation for external use | |
| EP3831358A1 (en) | Peptides and compositions for use in cosmetics and medicine | |
| JP2021147393A (en) | Oxidation stress inhibitor | |
| CN115322254A (en) | Lactoferrin, polypeptide derived from lactoferrin and application of polypeptide to inhibition and/or reduction of grease generation | |
| JP2022550991A (en) | Peptide-based cosmetic or dermatological treatment of the skin and its appendages | |
| WO2010024204A1 (en) | Wrinkle-diminishing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100616 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100616 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130322 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131029 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5423002 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |